Oper Wien

It’s time for our second post on WCLC22, which also happens to be on the hot KRAS G12C niche.

The first part analysing the sotorasib plus checkpoint combo was posted here for anyone who missed it.

This time around we’re going to explore different combinations and look at some of the fast-follower agents coming up on the rails.

After all, this is more than a two-horse race where the winner isn’t necessarily the first past the post, but rather the one either with the widest therapeutic window or who figures out the optimal combination partners.

Curious to learn more?  Check it out…

To continue reading our latest discussion on oncology new product development plus commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by